Gastrin stimulates growth of colon cancer

Owen E. Winsett, Courtney Townsend, Elena J. Glass, James C. Thompson

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Gastrin is trophic for normal gastric and colonic mucosa. We examined the potential trophic effects of chronic gastrin administration on the growth of mouse colon adenocarcinoma (MC-26). Thirty-three mice bearing transplantable MC-26 colon cancers were treated with varying doses (125, 250, or 500 μg/kg/day) of pentagastrin. Significant increases in tumor weight and DNA content were observed. Fundic mucosal weight and DNA content in these mice showed a dose-related trophic response. The weight of control fundic mucosa was 10 mg and rose to 20, 45, and 65 mg with increasing doses of gastrin. The DNA content of control fundic mucosa was 155 μg and rose to 220, 340, and 480 μg as the dose of gastrin was increased. Pentagastrin stimulated growth of the MC-26 colon cancer, but the threshold for gastrin-stimulated tumor growth was different from that of normal mucosal growth. The hyperplastic response of the fundic mucosa was increased by increasing gastrin doses; whereas, colon cancer hyperplasia was maximal at the lowest dose tested (125 μg/kg/day) and did not increase further with increasing doses of hormone. Mice bearing gastrin-stimulated tumors died at a significantly greater rate than did mice with untreated tumors (80% of control mice and none of the treated mice were alive at day 55). The effects of gastrin treatment on the growth of MC-26 colon cancer persist after treatment is discontinued; mice with tumors that were treated with gastrin for either 7 or 14 days and in which the treatment was stopped were all dead by 35 or 28 days, respectively, after the end of treatment.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalSurgery
Volume99
Issue number3
StatePublished - 1986

Fingerprint

Gastrins
Colonic Neoplasms
Growth
Pentagastrin
Mucous Membrane
DNA
Neoplasms
Weights and Measures
Gastric Mucosa
Tumor Burden
Hyperplasia
Colon
Adenocarcinoma
Hormones

ASJC Scopus subject areas

  • Surgery

Cite this

Winsett, O. E., Townsend, C., Glass, E. J., & Thompson, J. C. (1986). Gastrin stimulates growth of colon cancer. Surgery, 99(3), 302-307.

Gastrin stimulates growth of colon cancer. / Winsett, Owen E.; Townsend, Courtney; Glass, Elena J.; Thompson, James C.

In: Surgery, Vol. 99, No. 3, 1986, p. 302-307.

Research output: Contribution to journalArticle

Winsett, OE, Townsend, C, Glass, EJ & Thompson, JC 1986, 'Gastrin stimulates growth of colon cancer', Surgery, vol. 99, no. 3, pp. 302-307.
Winsett OE, Townsend C, Glass EJ, Thompson JC. Gastrin stimulates growth of colon cancer. Surgery. 1986;99(3):302-307.
Winsett, Owen E. ; Townsend, Courtney ; Glass, Elena J. ; Thompson, James C. / Gastrin stimulates growth of colon cancer. In: Surgery. 1986 ; Vol. 99, No. 3. pp. 302-307.
@article{46bd1ea1484d461babed347ee69f762e,
title = "Gastrin stimulates growth of colon cancer",
abstract = "Gastrin is trophic for normal gastric and colonic mucosa. We examined the potential trophic effects of chronic gastrin administration on the growth of mouse colon adenocarcinoma (MC-26). Thirty-three mice bearing transplantable MC-26 colon cancers were treated with varying doses (125, 250, or 500 μg/kg/day) of pentagastrin. Significant increases in tumor weight and DNA content were observed. Fundic mucosal weight and DNA content in these mice showed a dose-related trophic response. The weight of control fundic mucosa was 10 mg and rose to 20, 45, and 65 mg with increasing doses of gastrin. The DNA content of control fundic mucosa was 155 μg and rose to 220, 340, and 480 μg as the dose of gastrin was increased. Pentagastrin stimulated growth of the MC-26 colon cancer, but the threshold for gastrin-stimulated tumor growth was different from that of normal mucosal growth. The hyperplastic response of the fundic mucosa was increased by increasing gastrin doses; whereas, colon cancer hyperplasia was maximal at the lowest dose tested (125 μg/kg/day) and did not increase further with increasing doses of hormone. Mice bearing gastrin-stimulated tumors died at a significantly greater rate than did mice with untreated tumors (80{\%} of control mice and none of the treated mice were alive at day 55). The effects of gastrin treatment on the growth of MC-26 colon cancer persist after treatment is discontinued; mice with tumors that were treated with gastrin for either 7 or 14 days and in which the treatment was stopped were all dead by 35 or 28 days, respectively, after the end of treatment.",
author = "Winsett, {Owen E.} and Courtney Townsend and Glass, {Elena J.} and Thompson, {James C.}",
year = "1986",
language = "English (US)",
volume = "99",
pages = "302--307",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Gastrin stimulates growth of colon cancer

AU - Winsett, Owen E.

AU - Townsend, Courtney

AU - Glass, Elena J.

AU - Thompson, James C.

PY - 1986

Y1 - 1986

N2 - Gastrin is trophic for normal gastric and colonic mucosa. We examined the potential trophic effects of chronic gastrin administration on the growth of mouse colon adenocarcinoma (MC-26). Thirty-three mice bearing transplantable MC-26 colon cancers were treated with varying doses (125, 250, or 500 μg/kg/day) of pentagastrin. Significant increases in tumor weight and DNA content were observed. Fundic mucosal weight and DNA content in these mice showed a dose-related trophic response. The weight of control fundic mucosa was 10 mg and rose to 20, 45, and 65 mg with increasing doses of gastrin. The DNA content of control fundic mucosa was 155 μg and rose to 220, 340, and 480 μg as the dose of gastrin was increased. Pentagastrin stimulated growth of the MC-26 colon cancer, but the threshold for gastrin-stimulated tumor growth was different from that of normal mucosal growth. The hyperplastic response of the fundic mucosa was increased by increasing gastrin doses; whereas, colon cancer hyperplasia was maximal at the lowest dose tested (125 μg/kg/day) and did not increase further with increasing doses of hormone. Mice bearing gastrin-stimulated tumors died at a significantly greater rate than did mice with untreated tumors (80% of control mice and none of the treated mice were alive at day 55). The effects of gastrin treatment on the growth of MC-26 colon cancer persist after treatment is discontinued; mice with tumors that were treated with gastrin for either 7 or 14 days and in which the treatment was stopped were all dead by 35 or 28 days, respectively, after the end of treatment.

AB - Gastrin is trophic for normal gastric and colonic mucosa. We examined the potential trophic effects of chronic gastrin administration on the growth of mouse colon adenocarcinoma (MC-26). Thirty-three mice bearing transplantable MC-26 colon cancers were treated with varying doses (125, 250, or 500 μg/kg/day) of pentagastrin. Significant increases in tumor weight and DNA content were observed. Fundic mucosal weight and DNA content in these mice showed a dose-related trophic response. The weight of control fundic mucosa was 10 mg and rose to 20, 45, and 65 mg with increasing doses of gastrin. The DNA content of control fundic mucosa was 155 μg and rose to 220, 340, and 480 μg as the dose of gastrin was increased. Pentagastrin stimulated growth of the MC-26 colon cancer, but the threshold for gastrin-stimulated tumor growth was different from that of normal mucosal growth. The hyperplastic response of the fundic mucosa was increased by increasing gastrin doses; whereas, colon cancer hyperplasia was maximal at the lowest dose tested (125 μg/kg/day) and did not increase further with increasing doses of hormone. Mice bearing gastrin-stimulated tumors died at a significantly greater rate than did mice with untreated tumors (80% of control mice and none of the treated mice were alive at day 55). The effects of gastrin treatment on the growth of MC-26 colon cancer persist after treatment is discontinued; mice with tumors that were treated with gastrin for either 7 or 14 days and in which the treatment was stopped were all dead by 35 or 28 days, respectively, after the end of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022551915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022551915&partnerID=8YFLogxK

M3 - Article

C2 - 3952654

AN - SCOPUS:0022551915

VL - 99

SP - 302

EP - 307

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -